go-v.orgdoi

Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results

Roberto Lorenzetti, Cosimo Prantera · Clinical Investigation · 2013

  • DOI 10.4155/cli.13.96
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2013

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2013

Abstract

The cause of inflammatory bowel disease is not completely understood. However, there is now a strong evidence that resident intestinal bacteria, which are normally considered to be commensal, can initiate the pathological inflammation in a susceptible host. Although this may be a good rationale for antibiotic use in the treatment of these diseases, previous trials with different antibiotics have given controversial results while their long-term use is accompanied by an elevated number of adverse events.

Rifaximin is an oral, minimally absorbed (<1% of the ingested dose), antimicrobial agent that exerts its bactericidal activity in the intestinal lumen, and is apparently free of systemic side effects. The efficacy of a new gastroresistant formulation of rifaximin (rifaximin-extended intestinal release) in moderately active Crohn’s disease has been recently shown in a multicenter, randomized, double-blind trial. In open-label studies promising results have also been obtained in ulcerative colitis and pouchi...

Open the resolved locator · 10.4155/cli.13.96

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 00:25 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.13.96
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.